Open AccessGivosiran (Givlaari)
Author(s) -
Reimbursement Team
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.166
Subject(s) - reimbursement , medicine , hemin , medical emergency , emergency medicine , health care , intensive care medicine , heme , biochemistry , chemistry , economics , enzyme , economic growth
CADTH recommends that Givlaari should be reimbursed by public drug plans for the treatment of acute hepatic porphyria (AHP) in adults if certain conditions are met.
Givlaari should only be covered to treat patients who have experienced 4 or more attacks requiring either hospitalization, an urgent health care visit, or intravenous hemin in the year prior to the prescribing date.
Givlaari should only be reimbursed if prescribed by a clinician experienced in the management of AHP, if it is not used in combination with prophylactic hemin, and if the cost of Givlaari is reduced. Reimbursement of Givlaari should be renewed after 12 months if there is a reduction in the annualized attack rate.